search
Back to results

SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects

Primary Purpose

Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
SURGICEL Powder
Sponsored by
Ethicon, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemorrhage focused on measuring bleeding, broad area oozing bleeding, hemostat, topical hemostatic agents, adjunctive hemostats

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Pre-operative:

  1. Adult subjects ≥ 18 years requiring elective/non-emergent open or laparoscopic general, gynaecological, cardiothoracic, or urological surgical procedures;
  2. Subject or authorised representative has signed the approved Informed Consent;
  3. Subject(s) whose International Normalised Ratio is <1.5 within 24 hours of surgery.

    Intra-operative:

  4. Presence of an appropriate TBS identified intra-operatively by the surgeon;
  5. Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment.

Exclusion Criteria:

Pre-operative:

  1. Female subjects who are pregnant or nursing;
  2. Subject on anticoagulation medication (with exception of aspirin) prior to surgery. Washout periods for respective medications must be observed.

    If information is not readily available within the Instructions for Use (IFU), a conservative approach should be taken and intravenous heparin stopped 12 hours prior to surgery and 2 days prior for oral medication;

  3. Subject on antiplatelet/P2Y12 inhibitors medication prior to surgery. Platelet recovery times for respective medication must be observed. If information is not readily available within the IFU, a conservative approach should be taken and medication stopped 5 days prior to surgery.
  4. Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor;
  5. Subjects who are known, current alcohol and/or drug abusers;
  6. Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure.

    Intra-operative:

  7. Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product;
  8. Subject with TBS in an actively infected field [Class III Contaminated or Class IV Dirty or Infected (see Appendix 2 in in Section 15.2)];
  9. TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel;
  10. Major arterial or venous bleeding or major defects in arteries and veins;
  11. TBS where silver nitrate or any other escharotic chemicals have been applied;
  12. TBS is in, around, or in proximity to foramina in bone, or areas of bony confine, the spinal cord, or optic nerve and chiasm;
  13. TBS in urological procedures where plugging (blocking) of the urethra, ureter or a catheter is possible by the study product.

Sites / Locations

  • Ziekenhuis Oost Limburg
  • Universitair Ziekenhuis Gent
  • NHS Lothian (Western General Hospital)
  • Cambridge University Hospitals NHS Trust (Addenbrooke's Hospital)
  • Golden Jubilee National Hospital
  • Leeds Teaching Hospitals NHS Trust (St James's University Hospital)
  • Newcastle upon Tyne NHS Foundation Trust (Freeman Hospital)
  • Nottingham University Hospitals NHS Trust

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

SURGICEL Powder - Single arm

Arm Description

Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder

Outcomes

Primary Outcome Measures

Haemostatic Success at 5 Minutes
Proportion of subjects achieving haemostatic success at 5 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the Target Bleeding Site (TBS) any time prior to initiation of final fascial closure

Secondary Outcome Measures

Haemostatic Success at 3 Minutes
Proportion of subjects achieving haemostatic success at 3 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the TBS any time prior to initiation of final fascial closure
Haemostatic Success at 10 Minutes
Proportion of subjects achieving haemostatic success at 10 minutes following the application of SURGICEL Powder with no rebleeding that requires additional treatment at the TBS any time prior to initiation of final fascial closure

Full Information

First Posted
November 26, 2018
Last Updated
July 23, 2021
Sponsor
Ethicon, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03762200
Brief Title
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Official Title
A Prospective, Clinical Study Evaluating the Safety and Haemostatic Effectiveness of SURGICEL® Powder, in Mild or Moderate Parenchymal or Soft Tissue Bleeding During General, Gynaecological, Urological, and Cardiothoracic Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
November 26, 2018 (Actual)
Primary Completion Date
December 2, 2019 (Actual)
Study Completion Date
June 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ethicon, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical or ineffective during surgery (open, laparoscopic or thoracoscopic) in adult subjects (18 years or older). After application of SURGICEL Powder, the Target Bleeding Site (TBS) will be assessed for haemostasis (no detectable bleeding) at 3, 5, and 10 minutes from application and prior to initiation of closure. All enrolled subjects will be followed post-operatively through discharge and again at 30 days and 6 months post-surgery via phone call or office visit.
Detailed Description
This is an open label, prospective, single arm, multicentre, multispecialty, post-marketing clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis in the control of capillary, venous, and small arterial haemorrhage when ligation or other conventional methods of control are impractical or ineffective during surgery (open, laparoscopic or thoracoscopic) in adult subjects (18 years or older). Prospective subjects will be informed about the nature of the research, given the informed consent form (ICF) to read, and, if he/she understands the content, will be asked to provide consent by signing the ICF. Screening and enrolment will continue until at least 100 evaluable subjects from approximately eight (8) investigational sites, with an appropriate mild or moderate Target Bleeding Site (TBS) are included into the study. The TBS will be the only region evaluated for the primary endpoint and all secondary effectiveness endpoints. All enrolled subjects will be followed post-operatively through discharge, and via phone call or office visit at 30 days (+14 days) post-surgery. In addition, all enrolled subjects will receive a 6-month (+/-30 days) follow-up phone call or office visit to assess the occurrence of any serious adverse event (SAE) requiring surgical intervention and assessed as possibly related or related to the study treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhage
Keywords
bleeding, broad area oozing bleeding, hemostat, topical hemostatic agents, adjunctive hemostats

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SURGICEL Powder - Single arm
Arm Type
Other
Arm Description
Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
Intervention Type
Device
Intervention Name(s)
SURGICEL Powder
Intervention Description
SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
Primary Outcome Measure Information:
Title
Haemostatic Success at 5 Minutes
Description
Proportion of subjects achieving haemostatic success at 5 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the Target Bleeding Site (TBS) any time prior to initiation of final fascial closure
Time Frame
From application of SURGICEL Powder to 5 minutes after application
Secondary Outcome Measure Information:
Title
Haemostatic Success at 3 Minutes
Description
Proportion of subjects achieving haemostatic success at 3 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the TBS any time prior to initiation of final fascial closure
Time Frame
From application of SURGICEL Powder to 3 minutes after application
Title
Haemostatic Success at 10 Minutes
Description
Proportion of subjects achieving haemostatic success at 10 minutes following the application of SURGICEL Powder with no rebleeding that requires additional treatment at the TBS any time prior to initiation of final fascial closure
Time Frame
From application of SURGICEL Powder to 10 minutes after application
Other Pre-specified Outcome Measures:
Title
Number of Participants Experiencing a Thromboembolic Event
Description
Number of participants experiencing a thromboembolic event that was assessed as having either an unlikely, possible, probable or causal relationship to the study treatment
Time Frame
From application of SURGICEL Powder to 30 day follow-up visit
Title
Number of Participants With Post-operative Re-bleeding
Description
Number of participants of post-operative re-bleeding that was assessed as having either an unlikely, possible, probable or causal relationship to the TBS and requiring medical/surgical intervention
Time Frame
From initiation of final fascial closure to the 30-day follow up visit
Title
Number of Participants Experiencing a Serious Adverse Events Requiring Surgical Intervention and Related to SURGICEL Powder
Description
Number of participants experiencing a serious adverse event requiring surgical intervention and assessed as having either an unlikely, possible, probable or causal relationship to the study treatment
Time Frame
From time of SURGICEL Powder application to 6-month follow up visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pre-operative: Adult subjects ≥ 18 years requiring elective/non-emergent open or laparoscopic general, gynaecological, cardiothoracic, or urological surgical procedures; Subject or authorised representative has signed the approved Informed Consent; Subject(s) whose International Normalised Ratio is <1.5 within 24 hours of surgery. Intra-operative: Presence of an appropriate TBS identified intra-operatively by the surgeon; Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment. Exclusion Criteria: Pre-operative: Female subjects who are pregnant or nursing; Subject on anticoagulation medication (with exception of aspirin) prior to surgery. Washout periods for respective medications must be observed. If information is not readily available within the Instructions for Use (IFU), a conservative approach should be taken and intravenous heparin stopped 12 hours prior to surgery and 2 days prior for oral medication; Subject on antiplatelet/P2Y12 inhibitors medication prior to surgery. Platelet recovery times for respective medication must be observed. If information is not readily available within the IFU, a conservative approach should be taken and medication stopped 5 days prior to surgery. Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor; Subjects who are known, current alcohol and/or drug abusers; Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure. Intra-operative: Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product; Subject with TBS in an actively infected field [Class III Contaminated or Class IV Dirty or Infected (see Appendix 2 in in Section 15.2)]; TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel; Major arterial or venous bleeding or major defects in arteries and veins; TBS where silver nitrate or any other escharotic chemicals have been applied; TBS is in, around, or in proximity to foramina in bone, or areas of bony confine, the spinal cord, or optic nerve and chiasm; TBS in urological procedures where plugging (blocking) of the urethra, ureter or a catheter is possible by the study product.
Facility Information:
Facility Name
Ziekenhuis Oost Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
NHS Lothian (Western General Hospital)
City
Edinburgh
State/Province
Lothian
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Facility Name
Cambridge University Hospitals NHS Trust (Addenbrooke's Hospital)
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
Golden Jubilee National Hospital
City
Clydebank
ZIP/Postal Code
G81 4DY, GB
Country
United Kingdom
Facility Name
Leeds Teaching Hospitals NHS Trust (St James's University Hospital)
City
Leeds
ZIP/Postal Code
LS9 7TF
Country
United Kingdom
Facility Name
Newcastle upon Tyne NHS Foundation Trust (Freeman Hospital)
City
Newcastle upon Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
Nottingham University Hospitals NHS Trust
City
Nottingham
ZIP/Postal Code
NG7 2UH
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects

We'll reach out to this number within 24 hrs